Stocks · News reference

Dogwood Therapeutics Announces Virtual KOL Event On September 1 To Discuss Halneuron In Chemotherapy Induced Neuropathic Pain; Says Positive Interim Phase 2b Results To Be Reviewed

Aug 17, 2026, 12:31 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 13, 2026, 12:54 PMBenzinga Newsdesk
Dogwood Therapeutics Q2 EPS $(0.34) Misses $(0.14) Estimate
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.14) by 142.86 percent. This is a 82.91 percent increase over losses of $(1.99) per
Read original at benzinga
DWTX
SEC EDGARAug 13, 2026, 12:50 PMSEC EDGAR
8-K filing — Dogwood Therapeutics, Inc. (DWTX)
Filed: 2026-08-13 AccNo: 0001104659-26-095512 Size: 368 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
DWTX
BenzingaJul 20, 2026, 12:34 PMBenzinga Newsdesk
Dogwood Therapeutics Admits First 200 Participants In Its Current HAL-CINP Phase 2b Study To Evaluate Efficacy, Safety Of Halneuron
Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully enrolled the first
Read original at benzinga
DWTX